Cilatus Regulatory was selected by a US biopharmaceutical company to provide strategic and operational EU regulatory leadership to support the commercial launch and lifecycle…
Authoring of IND Module 3, US Client
US based biopharmaceutical company engaged Cilatus Regulatory to author the Phase 1 IND Module 3 for a recombinant protein. Working to tight timelines, Cilatus…
